The pharmaceutical industry doesn’t work the way most people imagine. The company whose name appears on a prescription bottle often didn’t manufacture the drug inside it.

In many cases, that company didn’t develop the manufacturing process either. What it did was discover the molecule, prove it works in clinical trials, and navigate regulatory approval. Everything else, the synthesis, purification, analytical testing, and commercial production, was handled by a partner.

This partnership-driven model has been growing for years, but in 2026 it’s no longer the exception. It’s how the majority of new drugs reach patients.

Understanding the different partnership structures and how they’ve evolved explains why some medicines get to market faster than others and why the choice of manufacturing partner has become one of the most consequential decisions a drug developer makes.

The Two Models That Define Pharmaceutical Outsourcing

The pharmaceutical outsourcing ecosystem is built around two distinct partnership models, and the difference between them matters more than the acronyms suggest.

A contract manufacturing organization, or CMO, provides production capacity. The sponsor develops the manufacturing process internally, transfers it to the CMO, and the CMO executes it. The relationship is primarily operational. The sponsor retains full ownership of the process knowledge and the CMO functions as an extension of the sponsor’s manufacturing floor.

A contract development and manufacturing organization, or CDMO, goes further. It develops the manufacturing process alongside the sponsor, or sometimes independently on the sponsor’s behalf, and then manufactures the product using that process. The relationship is both technical and operational. The CDMO contributes intellectual input to how the drug is made, not just the physical capacity to make it.

For companies trying to understand which model fits their program, a detailed comparison of cdmo and cmo structures clarifies where the two approaches diverge and what each one actually delivers across the drug development lifecycle.

Why the Industry Has Shifted Toward CDMOs

Ten years ago, the split between cdmo and cmo engagements leaned heavily toward pure contract manufacturing. Large pharma companies maintained substantial internal process development teams and only outsourced the production itself. The CMO model fit that operating structure well.

Several forces have shifted the balance. The drugs in today’s pipelines are more complex. Peptides, high-potency APIs, antibody-drug conjugates, and oligonucleotides all require specialized chemistry expertise that most sponsors don’t maintain in-house. Developing a viable manufacturing process for these molecules is itself a significant scientific undertaking, one that benefits from the pattern recognition a CDMO builds across hundreds of programs.

Emerging biotech companies have accelerated this trend further. A typical clinical-stage biotech has fewer than 100 employees, no manufacturing infrastructure, and limited process development experience. For these companies, the cdmo and cmo distinction isn’t academic. They need a partner that can develop the process from scratch, manufacture clinical supply, and eventually scale to commercial production. That’s a CDMO engagement by definition.

In 2025, 73% of FDA-approved drugs outsourced their API manufacturing. The majority of those relationships were CDMO engagements rather than pure CMO arrangements, reflecting how far the industry has moved toward integrated partnerships.

How Partnership Structure Affects Patient Outcomes

The choice between cdmo and cmo models might seem like an internal industry decision with no bearing on patients. In practice, it directly affects how quickly and reliably medicines reach the people who need them.

Speed to market is one dimension. CDMO partnerships that begin during candidate selection compress development timelines because the manufacturing process is designed with commercial scale in mind from the start. Pure CMO engagements that receive a late-stage process transfer often encounter scale-up problems that add months to the timeline, delaying patient access.

Supply reliability is another. CDMOs that developed the process understand its sensitivities and failure modes intimately. When deviations occur during commercial production, they can troubleshoot faster because they built the process. A CMO operating a transferred process may lack that depth of understanding, which can extend investigation and resolution times.

Quality consistency rounds out the picture. The FDA’s enforcement data shows that 74% of Complete Response Letters between 2020 and 2024 cited quality or manufacturing issues. Many of these traced back to process development gaps, insufficient analytical validation, or weak scale-up documentation.

CDMO partnerships that generate this documentation as a natural output of the development process produce stronger regulatory submissions than arrangements where manufacturing knowledge is fragmented across multiple organizations.

The Hybrid Models Emerging in 2026

The clean distinction between cdmo and cmo is blurring as new partnership structures emerge to meet the needs of modern drug programs.

Some sponsors engage a CDMO for early-stage process development and clinical manufacturing, then transfer the validated process to a lower-cost CMO for commercial production. This captures the CDMO’s development expertise while optimizing commercial manufacturing economics. The trade-off is technology transfer risk, which adds 12 to 18 months and requires careful analytical bridging between sites.

Other companies maintain dual CDMO relationships across different geographies, providing supply chain resilience while retaining the development depth that pure CMO arrangements lack. This model has gained traction since the BIOSECURE Act accelerated geographic diversification away from concentrated manufacturing regions.

A third emerging pattern is the integrated cdmo and cmo model, where a single partner offers both development-intensive and production-only engagement tiers depending on the program’s maturity. This gives sponsors flexibility to scale the relationship up or down as their needs evolve without changing partners entirely.

What This Means for the Future of Drug Access

The evolution of pharmaceutical partnership models isn’t just an industry efficiency story. It has direct implications for which therapies reach patients, how quickly they arrive, and whether supply remains reliable after launch.

As drug complexity continues to increase across peptides, gene therapies, and novel small molecules, the cdmo and cmo models will continue evolving. The partners who combine deep technical capability with regulatory experience and manufacturing reliability will play an outsized role in determining which innovations actually translate into accessible medicines.

Where Neuland Laboratories Fits

Neuland Laboratories operates as a CDMO with capabilities spanning complex small molecule and peptide API development and manufacturing.

With three cGMP-certified facilities, over 400 R&D scientists, and regulatory approvals from the FDA, EMA, and PMDA, Neuland supports pharma and biotech clients across the full spectrum of cdmo and cmo engagement models, from early process development through commercial-scale API supply.

Their integrated approach to development and manufacturing reflects the partnership depth that modern drug programs increasingly require.

FAQs

1. Can a company start with a CMO engagement and transition to a CDMO relationship later?

Yes, but the transition usually signals that the original arrangement didn’t provide enough technical depth. Moving from a CMO to a CDMO mid-program means the new partner must learn the molecule, evaluate the existing process, and potentially redesign steps that weren’t optimized for scale. Starting with the right engagement model from the beginning avoids this rework.

2. How do partnership models differ for generic drugs versus innovative new therapies?

Generic drug programs typically use CMO-style engagements because the manufacturing process is already established and documented in regulatory filings. Innovative therapies, particularly complex molecules without manufacturing precedent, almost always require CDMO partnerships where the process is developed from scratch. The distinction comes down to whether process knowledge already exists or needs to be created.

3. What risks should companies consider when splitting development and commercial manufacturing between different partners?

Splitting introduces several concrete risks:

• Technology transfer requires engineering batches and method revalidation at the receiving site
• Impurity profiles may shift due to equipment and environmental differences between facilities
• Regulatory documentation must be updated and resubmitted to reflect the new manufacturing site
• Timeline impact is typically 12 to 18 months, which can delay commercial launch

These risks are manageable but must be planned for from the start.

4. Do patients benefit more from cdmo or cmo partnership models?

Patients benefit most from whichever model produces a safe, effective medicine and delivers it reliably. In practice, CDMO partnerships tend to produce stronger regulatory submissions, faster development timelines, and more robust commercial supply because the manufacturing partner understands the process at a deeper level. For complex therapies where manufacturing quality directly affects clinical outcomes, the CDMO model generally delivers better results for patients.